Erschienen in:
25.10.2018 | ASO Author Reflections
ASO Author Reflections: Predicting the Response of Esophageal Adenocarcinoma to Chemoradiotherapy Before Surgery Using MicroRNA Biomarkers Offers Hope to Improve Outcomes by Tailoring Treatment to Predicted Responses
verfasst von:
George C. Mayne, BSc(Hons), PhD, David I. Watson, MBBS, MD, PhD, FRACS, FRCSEd(Hon), FAHMS, Karen Chiam, PhD, Damian J. Hussey, BSc(Hons), PhD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2018
Einloggen, um Zugang zu erhalten
Excerpt
Treatment for locally advanced esophageal adenocarcinoma usually involves neoadjuvant chemotherapy or chemoradiotherapy, followed by surgical resection. Neoadjuvant treatment improves survival rates, but only 30% of patients have complete pathological response, and survival is improved in only 10–15% of patients compared with surgery alone.
1 Furthermore, neoadjuvant chemoradiotherapy can increase morbidity and make some patients unfit for surgery. Whilst some patients do benefit from neoadjuvant therapies, many more might actually be subjected to treatment toxicity and have their surgery delayed for no survival advantage. …